NCT02229357 is a Phase 2 clinical trial of OrniFlu® inactivated vaccine in Avian Influenza, sponsored by Mahidol University.

Who is sponsoring NCT02229357?

NCT02229357 is sponsored by Mahidol University.

What drugs are being tested in NCT02229357?

Interventions in NCT02229357: OrniFlu® inactivated vaccine.

What condition does NCT02229357 study?

NCT02229357 studies Avian Influenza.

Is NCT02229357 still recruiting?

NCT02229357 is currently completed. Last updated 8 April 2015.

Last reviewed 2015-04-08 · How we verify

NCT02229357

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study

Completed Phase 2 Last updated 8 April 2015

What this trial tests

Phase 2 trial testing OrniFlu® inactivated vaccine in Avian Influenza in 60 participants. Completed in 1 September 2014.

Timeline

1 June 2014

Primary endpoint
1 September 2014

1 September 2014

Quick facts

Lead sponsor	Mahidol University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	60
Start date	1 June 2014
Primary completion	1 September 2014
Estimated completion	1 September 2014
Sites	1 location across Thailand

Drugs / interventions tested

OrniFlu® inactivated vaccine — full drug profile →

Conditions studied

Avian Influenza — all drugs for Avian Influenza →

Sponsor

Mahidol University

Who can join

Adults 18 to 49, any sex, with Avian Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of subjects exhibiting sero-responses in each of the assays (HAI, microneutralization) in the prime-boost and the control groups.
Time frame: 12 Months

Sponsor's own description

This study aim to compare immunogenicity of the inactivated H5 influenza vaccine single dose between subjects previously vaccinated with LAIV H5N2 and naïve subjects

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P, Boonnak K, Chamnanchanunt S, Puthavathana P, et al · · 2017 · cited 28× · PMID 28533093 · DOI 10.1016/s1473-3099(17)30240-2
Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses.
Jang H, Matsuoka M, Freire M. · · 2023 · cited 6× · PMID 37928529 · DOI 10.3389/fimmu.2023.1220610

Verify or expand the search:

Other recruiting trials for Avian Influenza

Currently open trials in the same condition.

NCT07240558 — Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) · Phase 3 · recruiting
NCT07275060 — Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart · Phase 4 · active not recruiting
NCT07019883 — A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults · Phase 1 · active not recruiting

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02229357 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 8 April 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02229357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing